A Phase I open label dose escalation study for the safety and tolerability of AZD2171 in solid tumors in Japan
Study identifier:D8480C00023
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I open label dose escalation study for the safety and tolerability of AZD2171 following single and multiple oral doses in patients in Japan with advanced solid malignancies
Medical condition
advanced solid tumor
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171
Sex
All
Actual Enrollment
40
Study type
Interventional
Age
20 Years - 75 Years
Date
Study Start Date: 01 Oct 2005
Primary Completion Date: 01 Jul 2007
Study Completion Date: 01 Jan 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Jane Robertson
AstraZeneca
